Alzamend Neuro Inc (NASDAQ:ALZN) price on Friday, June 13, rose 1.57% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.24.
A look at the stock’s price movement, the close in the last trading session was $3.19. Turning to its 52-week performance, $135.54 and $3.05 were the 52-week high and 52-week low respectively. Overall, ALZN moved -15.84% over the past month.
Alzamend Neuro Inc’s market cap currently stands at around $2.60 million, with investors looking forward to this quarter’s earnings report slated for in July.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend ALZN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ALZN’s current price about -10.58% and -37.55% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.36, while 7-day volatility ratio is 3.10% and 14.62% in the 30-day chart. Further, Alzamend Neuro Inc (ALZN) has a beta value of -0.28, and an average true range (ATR) of 0.59.
If we refocus on Alzamend Neuro Inc (NASDAQ:ALZN), historical trading data shows that trading volumes averaged 1.51 million over the past 3 months. The company’s latest data on shares outstanding shows there are 0.80 million shares.
The 2.65% of Alzamend Neuro Inc’s shares are in the hands of company insiders while institutional holders own 0.88% of the company’s shares. Current price change has pushed the stock -68.97% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ALZN stock continues to rise going into the next quarter.
